Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
November 29, 2007

Galapagos Inks $8.1M Alliance with Cystic Fibrosis Foundation Therapeutics

  • Galapagos is partnering with Cystic Fibrosis Foundation Therapeutics (CFFT) in a deal worth up to $8.1 million. The research will be conducted through Galapagos’ BioFocus DPI service.

    The joint effort will combine BioFocus’ expertise in natural product drug discovery and screening in cells derived from patients. Specifically, the research aims to identify small molecules derived from natural sources that improve the function of CFTR (cystic fibrosis transmembrane conductance regulator). This protein is found defective in people with cystic fibrosis.

    Galapagos will receive $2.4 million over the next two years and up to $5.7 million for research achievements. This collaboration adds to a previously established target discovery agreement between CFFT and Biofocus, signed in 2005.

  • You’re all set! Thank you for subscribing to GEN Highlights.